Notably, Zhang et al., in a trial with enrolled CRC patients (NCT02349724), suggested that third generation of CAR with CD28 and CD137 signaling did not exhibit enhanced cytokine excretion and cytotoxicity profile than second generation with CD28 signaling (Sureban et al. 2019). This evidence concerns the gene CD28 and colorectal carcinoma.